You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The latest news on next-generation sequencing.
NRG1 gene fusions, found most commonly in lung and pancreatic cancer, are generating interest among drugmakers as a new precision medicine indication.
Through the partnership, Strata will use its next-generation sequencing test to identify advanced cancer patients with mutations in the MAPK signaling pathway.
A consortium convened by Friends of Cancer Research has made progress in quantifying sources of TMB assay discordance and created a new test-alignment software tool.
Within the partnership, Strata Oncology will use its StrataNGS test to identify patients with NRG1 gene fusions who may be eligible to enroll in a Phase II trial for the drug.
The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.
BostonGene will analyze the tumors of patients enrolled in NEC or NEC-affiliated clinical trials and NEC will use the data to help improve treatment responses.
The initiative will offer a liquid biopsy tool that only requires a blood draw for cancer treatment selection instead of a tissue biopsy.
Burning Rock also said it will continue to develop companion diagnostics-related products based on next-generation sequencing technology.
Some oncologists said 10 mutations/Mb is an acceptable TMB cutoff in patients who are out of options, while others worry it will drive immunotherapy use in those unlikely to have a lasting benefit.
The findings underscore the utility of universal germline testing in young adults diagnosed with cancers that are more common in older populations.